Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals

This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date.

This vaccine technology could be used for immunization of stray dogs by an oral route. In developing nations, more than 90% of human exposure events and 99% of human deaths due to rabies are caused by rabid dogs. Using this vaccine with a broadly implemented oral vaccination strategy provides a promising opportunity for reducing transmission of rabies between stray dogs and, thereby, increasing protection for people.

Potential Commercial Applications: Competitive Advantages:
  • Wildlife and humane shelter rabies prevention and control programs
  • Improved rabies vaccines for pets and livestock
  • Humane, targeted approach to elimination of rabies reservoirs in feral animal populations
  • Safe and effective
  • Oral immunization is the most practical and efficient method of rabies vaccination of wildlife and feral animals
  • Vaccine has demonstrated protection in vivo
  • Recombinant, non-neuroinvasive virus expressing a neuroinvasive glycoprotein and/or pro-apoptotis gene safely induces a robust and desirable immunological response

Development Stage:
  • In vitro data available
  • In vivo data available (animal)


Charles Rupprecht (CDC)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 7,074,413 issued 2006-07-11
PCT Application No. PCT/US2001/009529
US Application No. 09/816,531
US Application No. 60/191,510

Morimoto K, et al. PMID 11348722

Licensing Contact:
Tara Kirby, Ph.D.
Email: tara.kirby@nih.gov
Phone: 240-669-5128

OTT Reference No: E-470-2013/0
Updated: May 24, 2016